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Growth of methioninewdependent human prostate
cancer (PC-3) is inhibited by ethionine combined with
methionine starvation
F Poirson-Bichat, G Gonfalone, RA Bras-Gon9alves, B Dutrillaux and MF Poupon
Institut Curie, Section de Recherche, CNRS-UMR 147, 26, rue d'Ulm, 75231 Paris Cedex 05, France
Summary Methionine (MET) is required for cell metabolism. MET endogenously synthesized from homocysteine (HCY) supports the
proliferation of normal cells, but not that of numerous malignant cells, as shown previously. MET starvation should have an anti-tumour effect,
and its deleterious effects on the hosts might be prevented by HCY. Anti-tumour effects of MET starvation must be reinforced by ethionine
(ETH), a MET analogue. MET dependency of PC-3, a human prostate cancer cell line, was studied in vitro. Proliferation of PC-3 cells,
cultivated in MET-free medium, was 29% compared with growth in MET+HCY- medium. Addition of HCY to MET-free medium increased the
proliferation rate to 56%. The concentration of ETH required to decrease the PC-3 cell proliferation rate to 50% (IC50) was 0.5 mg ml-1 in
MET-HCY- medium. ETH-induced inhibition was abolished by MET addition and was reinforced by HCY. PC-3 cell cycle was blocked in the
S-G2-phase after 30 h culture in the absence of MET; this blockage was not reversed by addition of HCY. ETH at the lC50 in MET-HCY+
medium blocked DNA replication. Apoptotic cells appeared after 30 h incubation in MET-HCY+ medium only when ETH was added. ATP pools
were decreased after 15 h of culture in MET-free medium. In vivo, MET starvation was obtained by feeding tumour-bearing mice a diet
containing a synthetic amino acid mixture as the protein supply, in which HCY replaced MET. Given to nude mice bearing xenografted PC-3,
from day 1 after grafting and for 3 weeks, this diet inhibited tumour growth (34% on day 20, P< 0.007); this effect was potentiated by ETH (200
mg kg-' day-' i.p.) (56% on day 20, P< 5 x 10-5). The differences between the effects of these two treatments were significant (P< 0.017) and
optimal on day 20. These data showed that combination of ETH and HCY slowed the proliferation of prostate cancer cells in vitro and in vivo,
decreased ATP synthesis and caused cell cycle arrest and apoptosis. Experimental therapy based on cancer cell MET metabolism deficiency
could be efficient for treating advanced prostate cancers refractory to current therapies.
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Prostate adenocarcinoma is the most common cancer and the
second leading cause of cancer death in men in the United States
(Wingo et al, 1995). Initially responsive to anti-androgen treat-
ments, metastatic prostate cancer inevitably progresses to an
androgen-independent state (Crawford et al, 1989). Chemotherapy
has little efficacy and is poorly tolerated by patients weakened by
cancer progression and advanced age. The need to discover new
targets for prostate cancer therapy is obvious. Gene therapy, by
stimulating the immune host defences, is an attractive approach
that is currently being explored (Simons, 1994). However, even if
this approach proves successful, it would require heavy biotechno-
logical support and would hardly be accessible to a majority of
patients. Other therapies must be intensively sought.
New targets must be identified, and the metabolic abnormalities
of cancer cells offer such opportunities (Bravard et al, 1992;
Lasserre, 1994). Metabolic anomalies are commonly found in
solid tumours and some of them have been known for decades
(Warburg, 1956). Among the metabolic abnormalities recurrently
found in cancers (Oudard et al, 1995; Miccoli et al, 1996), methio-
nine (MET) dependency and alterations of MET metabolism have
been found in many, if not in all, types of human tumours
(Breillout et al, 1990; Guo et al, 1993a; Poirson et al, 1996). MET,
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an essential amino acid, is required for the initiation of protein
synthesis by MET-tRNA formation and S-adenosylmethionine
synthesis (Ogier et al, 1993). S-adenosylmethionine enters into
either polyamine synthesis or the transmethylation pathway
(Figure 1). It is now well established that regulation and function
ofDNA, RNA and phospholipids are dependent on their methyla-
tion status and that polyamine synthesis contributes to prolifera-
tion (Kramer et al, 1990). MET must be endogenously synthesized
either by homocysteine (HCY) methylation in the presence of
betaine cofactor and 5-methyltetrahydrofolate or, putatively,
through the polyamine pathway (Redgate et al, 1995). Most MET
is supplied exogenously in food (Hoffman and Erbe, 1976).
Alterations of MET metabolism have been observed in in vitro
culture tumour cells (Mecham et al, 1983), and their MET depen-
dency was described as the inability of MET-dependent cells to
grow in MET- medium, the need for a higher MET supply than
that ofnormal cells and as the inability to use HCY as a precursor
for endogenous MET synthesis. Therefore, MET dependency led
to the formulation of MET-free diets to feed rats or mice bearing
experimental tumours (Breillout et al, 1987, 1990; Fiskerstrand et
al, 1994). In these diets, an amino acid mixture replaced proteins
and HCY replaced MET. HCY substitution was required for
animal survival and was well tolerated (Gaudard-de Weck, 1989).
These early studies led us to postulate that MET deprivation
could be reinforced by substitution of MET with its analogues
designed to be transported into and metabolized by the cells; these
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Figure 1 Metabolism of methionine. AK1 and AK3, adenylate kinases; ADK,
adenosine kinase
analogues might give rise to abnormal metabolites and compro-
mise the metabolism of treated cells. This approach has been
applied to prostate cancers: first, the MET dependency of a
hormone-independent prostate cancer cell line (PC-3, established
by Kaignh et al, 1979) was determined in vitro; then, the effects of
MET starvation and ofethionine (ETH), a MET analogue, in vitro
and in vivo on the growth ofxenografted human prostatic tumours
were studied.
MATERIALS AND METHODS
Cell culture
PC-3 cell line, established from a hormone-independent human
prostate cancer, and DU-145, established from a hormone-depen-
dent human prostate cancer, were used (Guo et al, 1993; Stem and
Hoffman, 1986). Cells were maintained in RPMI-1640 medium
(Sigma) supplemented with 10% fetal calfserum (FCS) (Dutscher,
Brumath, France), penicillin G (102 IU ml-), streptomycin
(50 gg ml-') and glutamine (2 mM) (Sigma) at 37°C in a 5%
carbon dioxide 95% air humidified incubator. For experiments,
cells were harvested from cultures during their exponential growth
phase with 0.5 mg ml-' trypsin ethylenediaminetetraacetic acid in
phosphate-buffered saline (PBS) (Sigma).
Proliferation assays
Cells (105) were plated in 24-well polystyrene plates (ATGC,
Noisy-le-Grand, France), in triplicate, in 10% FCS RPMI-1640
medium with antibiotics and glutamine as described above, and
incubated for 24 h in a 5% carbon dioxide atmosphere at 37°C.
Then, the medium was replaced by aMET-free medium consisting
of 10% dialysed FCS (depleted in amino acids), MET-free RPMI-
1640, 100 gM folic acid, 1.5 gM hydroxocobalamin, with anti-
biotics and glutamine and with or without 100 gM HCY (Sigma).
Increasing concentrations ofETH (Sigma 0.01-2.5 mg ml-') were
added and cells were incubated for 72 h. Cell monolayers were
fixed for 1 h in methanol, stained with methylene blue (1 mg ml-')
in PBS for 1 h, then washed extensively with tap water. One
millilitre of 0.1 M hydrochloric acid was added to each well and
the absorbance of each well was measured (wavelength 620 nm)
with a spectrophotometer (LP500, J Bio, Les Ulis, France). The
ratio of the mean of the absorbance of cells cultivated in assay
medium to that ofcontrol (MET+HCY-) x 100 gave the cell prolif-
eration rate over a period corresponding to two doubling times
(72 h). Each assay was performed in five separate wells. The mean
was calculated from three independent experiments. The cell
proliferation index was calculated as the ratio of the proliferation
rate in assay medium to that in the same medium with ETH x 100.
The concentrations of ETH inducing 50% inhibition of prolifera-
tion (IC50) were determined from the growth curves of cells
cultured in the presence of increasing ETH concentrations. The
statistical significance of the differences between the cell prolifer-
ation rate in each medium was calculated using Student's t-test.
ATP content measurement
ATP was quantified by means of a bioluminescence assay using a
Lumac biocounter M1500 (Lumac Perstorp Analytical, Bezons,
France). PC-3 cells (105 per well in 24-well plates, run in tripli-
cate) were cultured in MET-HCY- or MET-HCY+ medium (HCY,
100 gM), with ETH (0.5 mg ml-') or without. Plates were incu-
bated at 37°C for 3, 15 and 24 h. Then, 1% trichloroacetic acid in
water (Sigma) was added to the cell extract. ATP was measured
in 450 gl ofdistilled water in which 20 gl ofluciferine-luciferase
(40 mg ml-') (Sigma), lOpI of the sample and 10 gl of standard
ATP (5.04 x 10-8 M; Sigma) were added successively to the lumi-
nometer tubes (Lumac). Luminescence was measured immedi-
ately. Results were expressed as percentages of ATP nmol 104
treated cells divided by ATP nmol 10 6control cells x 100. Mean
percentage was calculated from three independent experiments.
The statistical significance of the differences between the ATP
contents in each medium was calculated using Student's t-test
from five separate ATP measurements.
Effects on cell cycling
PC-3 cells were cultivated in MET-HCY- or MET-HCY+ medium,
with or without ETH at its IC50 concentration, for 30 h in 75-cm2
plastic culture flasks (ATGC). Bromodeoxyuridine (BrdU, Sigma)
at a concentration of 30 gM was added for 15 min. The cells were
permeabilized, labelled with a rat anti-BrdU antibody (Seralab,
Sigma), diluted 1:25 in buffer and subsequently with fluorescein
isothiocyanate-conjugated goat anti-rat antibody (Cliniscience,
Paris, France) diluted 1:50. Cells were incubated with propidium
iodide-PBS (1:50, v/v, Sigma) and then subjected to flow cytom-
etry (Becton Dickinson). Data were analysed automatically by a
LYSYS program and results expressed as histograms. Percentages
ofthe cells present in areas corresponding to each phase ofthe cell
cycle were calculated.
Determination of programmed (apoptotic) cell death
Programmed cell death was evaluated using a cellular DNA
fragmentation kit (Boehringer Mannheim, Germany). The assay is
based on the quantitative sandwichenzyme-linked immunosorbent
assay principle using two mouse monoclonal antibodies directed
against DNA and BrdU respectively. This procedure enables
the specific detection and quantification of BrdU-labelled DNA
fragments.
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Table 1 Composition of the two diets in which the protein content was
replaced with specific amino acid mixtures
Component g per 100 g Component g per 100 g
Lipids 11 Mineral salts 5
Colza oil 2.2 CM 2056c 5
Corn oil 8.8 Potassium iodide 0.00325
Proteins 14 Potassium alum 0.0005
L-arginine 0.048 Manganese sulphate 0.000375
L-lysine 0.655 Sodium fluoride 0.00015
L-cysteine 0.2415 Zinc sulphate 0.0024
L-tryptophan 0.1395 Cupric sulphate 0.0015
L-glycine 0.138 Vitamins 0.37
L-isoleucine 0.92 Vitamin A 0.0004
L-leucine 1.515 Vitamin Bi 0.002
L-phenylalanine 0.745 Vitamin B2 0.002
L-threonine 0.58 Vitamin B6 0.002
L-valine 0.97 Vitamin B,2 0.000002
L-histidine 0.42 Vitamin C 0.0333
L-tyrosine 0.81 Vitamin D3 0.0000125
L-alanine 0.437 Vitamin E 0.03
L-serine 0.735 Vitamin K3 0.0005
L-proline 1.47 Niacin 0.0025
L-aspartic acid 1.08 Choline 0.2
L-glutamic acid 3.375 Calcium pantothenate 0.005
D.L-methioninea 0.3 Folic acid 0.0002
D.L-homocysteineb 0.4 Inositol 0.085
Sugar Biotin 0.0001
Saccharose 5 Cellulose 8
Starch to complete 100
aMET+HCY- diet. bMET-HCY+ diet. cSalt mixture prepared by UAR
(Villemoisson, France).
In vivo studies
Animals
Swiss (nu/nu, male) mice, 8 weeks old, were bred in the animal
facilities of Institut Curie, Paris, France. The animals were main-
tained under specified pathogen-free conditions. Their care and
housing were in accordance with institutional guidelines from the
French Ethical Committee (Ministere de l'Agriculture, Paris,
France) and under the supervision ofauthorized investigators.
Diet
Mice were fed a regular diet of standard mouse pellets or a MET-
free diet supplemented with HCY (MET-HCY+) or with MET
(MET+HCY-), all prepared by UAR (Villemoisson, France). Per
100 g of diet, these two diets contained 11 g ofcolza/corn oil, 5 g
of mineral salts and vitamins, 5 g of saccharose and completed to
100 g with corn starch. An amino acid mixture containing MET or
HCY (0.3 and 0.4 g 100 g' respectively) was prepared and added
to the previous mixture. The MET-depleted diet was prepared
according to the recipe of regular diets for experimental rats and
mice (Table 1). These diets were designed to meet a daily MET
requirement of 1 g kg-' body weight and a daily food requirement
of I0g day-'.
Tumours
Xenografts were established by implantation of tumour samples
taken from tumours previously obtained by a subcutaneous injec-
tion of 2 x 106 PC-3 cells (viability 90%) into the flank of nude
mice. DU-145 cells were not tumorigenic. Xenografted PC-3
tumours were then maintained by three to six successive passages
from mouse to mouse. Tumour-bearing mice were randomly
divided into groups of ten animals. Therapeutic diet was started 1
day after grafting. Each mouse was identified by a code number.
ETH (200 mg kg-') was injected intraperitoneally (i.p.) daily 5
days after grafting and for 3 weeks. The volume of each mouse's
tumour was measured every 3 days and mice were weighed
weekly. Tumour growth was assessed by measuring two perpen-
dicular diameters with a caliper. Tumour volume (V) was calcu-
lated as (Poupon et al, 1993):
V=a2x b/2
were a is the width ofthe tumour in mm and b is the length ofthe
tumour in mm.
Tumour growth inhibition was calculated as the ratio between
the mean volume in the treated group and that ofthe tumours in the
control group at a given time x 100. The statistical significance of
the differences between the tumour volumes reached in each group
was calculated using Student's t-test. Tumour doubling time was
evaluated as the delay in hours necessary to double the tumour
volume during exponential growth, calculated from the day when
the volume equalled 200 mm3 (initial size before exponential
growth phase) to the day it measured 400 mm3. Mice were sacri-
ficed by prolonged anaesthesia when the tumour volumes reached
2000 mm3 in the control group.
Diet and ETH combinations
MET-HCY+ orMET+HCY-diets were fed totumour-bearing mice.
Daily i.p. injections of ETH (200 mg kg-') and diet were given
simultaneously for 3 weeks, then only the therapeutic diet was
continued.
RESULTS
Methionine dependency and effect of HCY on cell
proliferation
Cell proliferation rates of PC-3 and DU-145 cell lines cultured
in MET-free RPMI medium (MET-), supplemented with 10%
dialysed FCS, were determined and compared with those of the
same cells grown in MET+ medium (control medium). In control
medium, the doubling time of both lines was 26 h and was not
affected whether the serum was dialysed or not. Proliferation rate
ofPC-3 was greatly reduced to 29% in MET-free medium and that
ofDU-145 to 78%. Addition of 100 ,UM HCY to MET-free medium
allowed the PC-3 cells to increase their proliferation rate to 56%,
although it remains well below their control rate. DU-145 cell
proliferation, which was poorly affected in MET-free medium,
recovered quite completely when HCY was present (86%). These
experiments led to the conclusion of the MET dependency of the
PC-3 line, whereas DU-145 was not. Addition of HCY to MET+
medium (MET+HCY+) led to a significant decrease in the prolifer-
ation rate ofPC-3 cells (71%; P <0.01), when compared with their
growth in MET+HCY- medium, showing an inhibitory effect of
HCY in the presence of MET. DU-145 cells were not affected by
HCY addition.
Anti-proliferative effects of ETH
Modalities of ETH inhibition were studied using the PC-3 cells.
The cell proliferation was measured afteraddition ofETH to culture
medium at 0.5 mg ml', corresponding to the IC50 previously
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Figure 2 Time-dependent effects of ETH at constant concentration (0.5 mg ml-') on the proliferation rate of the PC-3 cell line in the presence of MET and/or
HCY in the culture medium: MET+HCY-, MET+HCY+, MET-HCY+, MET-HCY-. Open symbols, without ETH; closed symbols, with ETH. Proliferation rates were
calculated as the ratio of the mean absorbance of cells cultivated in assay medium to that of control (MET+HCY-) x 100, after staining with methylene blue and
hydrochloric acid extraction as indicated in Material and methods
measured in MET-HCY-. Anti-proliferative effects of ETH were
clearly detectable 48 h after the onset ofincubation, in MET-HCY+.
MET starvation induced areduction in cell proliferation, as early as
48 h after the start of culture. The additional effect of ETH was
evaluated by comparison with that ofthe media to which ETH was
added (Figure 2). In MET-HCY+ medium, ETH generated cell
proliferation indexes of 0.66 and 0.41 after 48 and 72 h ofincuba-
tion respectively. In MET-HCY- medium, the cell proliferation was
already greatly reduced; 29% of the remaining proliferation after
72 h of culture shortening the range of an additional inhibition by
addition ofETH. Cell proliferation indexes were 0.86 and0.76 after
48 and 72 h respectively. Effects ofETH were also measured in the
presence of MET. Anti-proliferative effect of ETH obtained in
MET+ medium did not exceed 20%, suggesting that MET was used
preferentially to ETH.
Effects of MET deprivation and ETH on ATP content
The ATP contents ofPC-3 cell extracts were measured after 3, 15
and 24 h ofculture in MET-HCY+ or MET-HCY- medium with or
without ETH (0.5 mg ml'), when cell proliferation inhibition is
not yet measurable by the colorimetric assay used; the total ATP
extracted from cells cultured in MET+HCY- medium was consid-
ered to be the 100% reference (Table 2). After 15 h of incubation
in MET-free medium, when the cells were still proliferating, the
ATP pools were very low in both media regardless of whether
ETH was added or not.
Cell cycle alterations
The cell cycling of PC-3 cells was analysed after a 30-h incuba-
tion, previously determined to be optimal for observing cell cycle
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Table 2 Effects of ETH (0.5 mg ml-') on the ATP content of PC-3 cells
assessed after different durations of cell culture in MET-free medium with or
without HCY
Medium ATP content rate (%)
ETH- ETH+
3h 15h 24h 3h 15h 24h
MET-HCY- 110±5 58±4 1.6±0.3 63±7 65±5 2.4±0.3
MET-HCY+ 87±3 26±3 2.3±0.2 68±6 37±3 2.2±0.5
ATP contents measured in extracts of PC-3 cells are expressed as the
percentages of (ATP nmol 10-6 treated cells divided by ATP nmol 10-6 control
cells) x 100.
Table 3 Evaluation of the effects of ETH treatment associated with MET
starvation in the presence or absence of HCY on PC-3 cell cycling
Percentage of cells per phaseb
Mediuma ETH Gi S G2
Standard RPMI No 46 39 15
MET-HCY- No 42 31 21
MET-HCY- Yes 45 6 (31)c 18
MET-HCY+ No 50 24 26
MET-HCY+ Yes 40 6 (30)c 24
aAil with dialysed fetal calf serum, as indicated in Materials and methods.
bThe percentage of cells in each phase was determined after 30 h of cell
culture in each medium. cThe numbers in parentheses are the percentages
of cells blocked in S-phase (determined by the DNA content vs BrdU
incorporation), as determined by cytofluorometry.
* R2 *~~'~jj~A R2
....
i ; R~~~4 R2 R2 p
Propidium iodide content
Figure 3 Cytofluorometric analysis of cell cycling BrdU-labelled PC-3 cells
grown in MET+HCY- (control) (A), MET-HCY+ (B) or MET-HCY+ETH (C) (0.5
mg ml-'-containing medium. The red fluorescence represents the propidium
iodide (PI) uptake as a function of the cell volume and the green
fluorescence represents the cycling of cells labelled with fluoresceinated anti-
BrdU serum (FITC). R2, S-phase; R3, G1-phase; R4, G2-phase
alterations (Table 3, Figure 3). When cultured in MET-HCY- or
MET-HCY+ medium, cells were blocked in late S-phase. Addition
of ETH to MET-HCY- medium further decreased by fivefold the
percentage ofcells replicating their DNA, aconstant percentage of
cells being arrested in S-phase (31%). The cells blocked in S-phase
were determined by the DNA content vs BrdU incorporation. The
percentages ofcells in the G,- and G2-phases were similar to those
grown in RPMI. Culturing cells in MET-HCY+ medium vs RPMI
only moderately affected the distribution according to phase:
fewer in the S-phase (24% vs 39% in the control medium), higher
100-1 -Q--- Control
0-
Co Q
0
0
0.
-4- ETH 0.1 mg ml-
-A- ETH 0.5 mg ml-
U-- ETH 2 mg ml-
Incubation time (h)
Figure 4 Percentage of DNA fragmentation in PC-3 cells detached from
monolayers as a function of the ETH concentration in MET-HCY+ medium
in G2-phase (26% vs 15% in the control medium) and similar
values in G,-phase. The addition of ETH to MET-HCY+ medium
further decreased by fourfold the percentage of cells replicating
their DNA in S-phase; 30% of cells were blocked in S-phase,
unable to replicate their DNA.
Apoptosis
ETH-induced apoptosis was quantitatively evaluated using a tech-
nique based on the metabolic BrdU labelling of DNA and the
detection of released BrdU-labelled fragments. Cells were incu-
bated in various concentrations of ETH in MET-HCY+ medium.
For cultured cells growing as monolayers, only apoptotic cells
become detached and DNA fragments can be detected in the
supernatant. Results are expressed as a function of the incubation
time (Figure 4). Apoptosis was maximal after 30 h of culture in
medium containing 0.5 mg ml-' ETH.
Anti-tumour effects of a MET-depleted diet and ETH on
xenografted prostate cancer
Adult male mice received xenografts ofPC-3 prostatic tumour and
were randomly distributed into groups of ten. One day after
tumourimplantation, a group ofmice fed aregulardiet was kept as
the control (Table 4, Figure 5); the other groups were fed a diet
containing amixture ofamino acids including eitherMET orHCY.
The tumour growth of mice fed a MET-containing diet did not
differ from that of the control group (data not shown). The
MET-HCY+ diet was well tolerated. On day 20, a 3% loss ofbody
weight was noted compared with the weight on the first day after
graft; this diet generated mean inhibitions of tumour growth of
34% (P < 0.007) on day 20 and 51% on day 32. Another group of
ten mice was fed a MET-HCY+ diet and simultaneously received
i.p. injections of ETH daily (200 mg kg-'). This ETH dose was
calculated to be the maximal dosage that could be given to mice,
taking into account ETH solubility and the amount of excipient
that can reasonably be administered to mice (0.25 ml per injec-
tion). This treatment caused an initial weight loss (7% compared
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Table 4 Effects of a MET-free diet, alone or associated with ETH, on the growth of PC3, a human prostate cancer grafted into nude mice
Dieta ETH treatment Number of mice per group Weight variations Tumour doubling time Mean tumour volume ± s.d. in mm3
(%) (h)b
mean ± s.d. mean ± s.d. Day 20 Day 32
(% tumour growth inhibition)
Regular diet 10 Gain 16.6+ 0.3 48+4 1170 + 128 3373 ±473
MET-HCY+ diet 10 Gain 3.2+0.1 94 8 777± 62 (34%) 1717 ± 282 (51%)
MET-HCY+ diet ETH 10 Loss 6.6 ± 0.2 121 ± 10 518 + 46 (56%) 1621 + 188 (48%)
(200 mg kg-1 day-l)c
aDiets were fed to tumour-bearing mice for 32 days starting on day 1 after grafting. bTumour doubling time was defined as the mean delay in hours necessary for
tumours to double their volume. cDaily bolus i.p. injection of ETH was started 5 days after grafting and was continued for 20 days.
m
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Diet +ETH 200 mg kg-' Diet alone
Figure 5 Mean tumour volume of PC-3 tumour-bearing mice fed either a
regular diet (0) or a MET-HCY+ diet with (A) or without (O) ETH as specified
in the figure
with that on the first day) but the weight of the mice stabilized
indicating minimal toxicity, even ifthese mice did not have a gain
of weight like controls. This treatment was well tolerated, and it
generated mean inhibition of tumour growth of 56% on day 20.
Anti-tumour efficacy ofETH combined with the MET-HCY+ diet
was statistically significantly different (P < 0.017, on day 20) from
the effect of the diet alone. The doubling time (time necessary to
grow from 200 to 400 mm3) of exponentially growing PC-3
tumours was 48 h. Under the MET-HCY+ diet or the MET-HCY+
diet combined with ETH treatment, the tumour doubling times
were prolonged to 94 h or 121 h respectively. On day 32, when
only diet therapy continued, the differences between the two
therapeutic groups were less marked.
DISCUSSION
Cellular MET dependency is defined under experimental condi-
tions as the inability ofcells to grow in a MET-free medium that is
notreversed by HCY addition, its endogenous synthesis precursor.
This dependency was responsible for the in vivo anti-tumour
effect of MET-free diets, as shown by Breillout et al (1987) and
Poirson et al (1996). Breillout et al (1987) demonstrated that MET
dependency of rat sarcoma cells reflected their malignancy:
metastatic sublines were more MET dependent than the non-
metastatic ones. Moreover, loss ofMET dependency by adaptative
selection ofMET-dependent cancer cells to MET-free medium led
to the loss of tumorigenicity, thereby supporting the idea that the
most advanced cancers are more MET dependent.
PC-3 cell proliferation was much more MET dependent in vitro
than that of DU-145. PC-3 cells completely ceased to proliferate
in the absence of MET and HCY, while DU-145 cells divided,
suggesting that this proliferation might be salvaged by an active
endogenous MET synthesis (Figure 1). The limited effect ofHCY
on PC-3 proliferation in the absence of MET indicates that
endogenous MET synthesis is strongly defective. Reduction of
PC-3 proliferation in MET+HCY+ medium might be caused by an
increased intracellular HCY concentration that may further aggra-
vate the metabolic defect ofendogenous MET synthesis pathways
in these cells. These two observations (lack of salvage by HCY
addition in MET-free medium and inhibition by HCY in the pres-
ence ofMET) converge, pointing out the defective MET synthesis
pathway in PC-3 and its inhibition by excess HCY. That HCY was
able to attenuate the inhibition ofDU-145 proliferation caused by
the absence of MET indicates that endogenous MET synthesis is
efficient in vitro in our experiments.
Anti-proliferative efficacy ofETH indicates that ETH is able to
replace MET, and the complete loss ofits efficacy in the presence
of MET reinforces this supposition. The early decrease (3 h incu-
bation) of the ATP pool induced by ETH compared with the slow
ATP decrease induced by MET deprivation could mean that ATP
is used for ETH adenosylation and that ATP synthesis resulting
fromS-adenosylhomocysteine hydrolase is lowered (see Figure 1).
ETH is a structural MET analogue in which the methyl of MET
is replaced by an ethyl. Because spatial steric hindrance between
the methylated and ethylated groups is approximately the same,
wepostulated that adenosylation ofETHby S-adenosylmethionine
transferase would lead to the synthesis ofaberrant metabolites (S-
adenosylethionine) that, in turn, would alter the methylation of
DNA, RNA orphospholipids. In Saccharomyces cerevisiae, it was
shown (Colombani et al, 1975; Kim et al, 1992) that ETH inhib-
ited S-adenosylmethionine transferase and that this inhibition
interfered with MET function. ETH can inhibit the methylation of
newly replicated DNA (Cox and Irving, 1977) at various methyla-
tion sites and to different extents, suggesting that the actions of
enzymes responsible for the methylation ofsuch sites are differen-
tially suppressed by S-adenosylethionine (Boehm and Drahovsky,
1981). Moreover, alternatively, ETH can also enter into protein
synthesis as demonstrated by the incorporation of radioactively
labelled ETH (Levine and Tarver, 1951).
Tumour cell alterations associated with slower proliferation
owing to MET starvation and ETH addition were studied.
Although it was possible to study the behaviour ofcells in vitro in
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MET-HCY- medium, feeding tumour-bearing mice a MET-HCY-
diet was not compatible with tumour host survival. For this reason,
the in vitro behaviour of cells was studied in a medium containing
HCY in place of MET. Our study focused on PC-3 cells that were
tumorigenic innudemice andenabledin vivo assessmentofourther-
apeutic strategy. Cellcycle was altered differently aftera 30-hculture
depending on the treatment. MET deprivation alone without HCY
markedly increased the number of cells in G2-phase and decreased
the numberofcells in the S-phase (Guo et al, 1993b; Hoffman, 1993;
Hoffman and Jacobsen, 1980). The addition ofHCY aggravated the
amplitude of these alterations. Addition of ETH sharply blocked
DNA-replicating cells during S-phase (Guo et al, 1994).
ETH induced a high level ofapoptosis with DNA fragmentation
being detected only in detached cells as described previously
(Wyllie, 1992). In comparison with the effects of apoptosis-
inducing drugs, such as camptotecin (Bomer et al, 1995), ETH-
induced apoptosis occurred much earlier (30 h after ETH vs 48 h
after camptotecin) and to a greater extent (100% in a non-adherent
cell population vs 27% ofnon-adherent cells representing approx-
imately 30% ofthe plated cells respectively).
In trying to elucidate how the MET pathways are altered by the
MET-HCY+ diet combined with ETH, we hypothesized that, in the
case of MET starvation, HCY does not support endogenous MET
synthesis, and accumulates and retroinhibits S-adenosylhomo-
cysteine hydrolase, thereby restricting the ATP synthesis. A
decrease in proliferation is observed, but without apoptosis. Cell
cycling is altered and only a small fraction of cells is able to pass
through the S-phase with a high proportion ofcells being blocked
in the G2-phase, as though they were not able to divide. In the case
ofMET starvation associated with ETH, ETH enters the synthesis
of S-adenosylethionine, consumes ATP and contributes to the
rapid lowering of the ATP pool. Ethylation of DNA could be
responsible for apoptosis, not seen with MET starvation alone,
leading to a blockage ofDNA replication.
These tentative explanations raise many questions. Defective
endogenous MET synthesis could explain the MET dependency,
and several hypotheses have been proposed. MET synthesis
depends on methionine synthase activity and cofactors, betaine,
5-methyltetrahydrofolate and cyanocobalamin. Each of these
cofactors might be defective in tumour cells, leading to less MET
synthesis. Studies have shown that some MET-dependent cell lines
lack sufficient cobalamin to assure HCY methylation (Liteplo et
al, 1991; Pezacka et al, 1992). MET dependency might also be a
result of the low availability of HCY that would be metabolized
in the transsulphuration pathway (Figure 1), which requires
cystathionine j-synthase. However, no specific increase in
cystathionine P-synthase activity has been found in MET-depen-
dent cells (Judde et al, 1989). Growth inhibition induced by HCY
in the presence ofMET mightresult in an excess ofHCY known to
inhibit S-adenosylhomocysteine hydrolysis, thereby slowing down
the transmethylation pathway.
We demonstrated in vivo that MET-depleted diets effectively
decreased metastatic potential and tumorigenicity in an experi-
mental rat model (Breillout et al, 1987). In the present experiments
done on an advanced human prostate cancer xenografted into nude
mice, anti-tumour effects were obtained by subjecting tumour-
bearing nude mice to MET starvation combined with ETH, a MET
analogue. This type oftumour is known to be refractory to current
therapies. MET dependency ofprostate cancer opens a still under-
explored therapeutic approach. Further studies on a variety of
prostate cancer models are required to evaluate whether MET
dependency and ETH sensitivity are general features of these
tumours and to determine whether this therapeutic strategy could
be successful, namely at an advanced, hormone-independent stage
ofprogression, as observed with the PC-3 model.
ABBREVIATIONS
MET, methionine; HCY, homocysteine; ETH, ethionine; FCS,
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deoxyuridine; LHRH, luteinizing hormone-releasing hormone;
s.d., standard deviation.
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